Please login to the form below

Not currently logged in
Email:
Password:

apceth names Ulrike Verzetnitsch as chief technical officer

She joins from Takeda, with immediate effect

edit-apceth-Ulrike-VerzetnischCell therapy company apceth has appointed Ulrike Verzetnitsch in the newly created role of chief technical officer.

In the position, Verzetnitsch will lead apceth's production facilities and operations and continue the expansion of its fee-for-service GMP manufacturing business.

Commenting on the appointment, Christine Guenther, CEO of apceth, said: “apceth has recently started phase II of the world's first clinical trial with genetically modified mesenchymal stem cells in cancer indications and is simultaneously increasing its manufacturing capacity and capabilities as a CMO. It is therefore a very exciting time for us to welcome Ulrike to the team.

“Her experience will complement our management team and help drive apceth forward.”

She joins from Takeda, where she was head of the production unit based in Singen, Germany. Prior to that, Verzetnitsch held the role of director of production at Baxter, where she focused on strategic tasks in the final container operation of vaccines and plasma-based and recombinant products.

As part of her role, she gained experience in the manufacturing of products for worldwide distribution in compliance with the FDA, EMEA, Japanese and other guidelines.

28th April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics